For BIG DATA
We possess a growing repository of healthy donors’ de-identified human stem cell genome sequence data sets. The big data-driven drug development field has been advancing, allowing for more precise identification of therapeutic targets and drugs tailored to specific diseases and clinical scenarios. These data sets also have the potential to significantly contribute to public health programs by analyzing population-specific genetic susceptibility to diseases and identifying protective genetic factors, such as resistance to infection, to prevent the occurrence of diseases
Furthermore, acquiring and analyzing genome-wide SNPs and T-cell repertoire can offer unbiased estimates of genetic diversity, serving as a foundation for personalized medicine
